Cancer combo trial pulled before it even started
NCT ID NCT04031872
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aimed to test a combination of two drugs—LY3200882 and capecitabine—in people with advanced colorectal cancer that had stopped responding to chemotherapy. The goal was to see if the combination could re-sensitize tumors to treatment. However, the trial was withdrawn before enrolling any patients, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LY3200882 (a TGF-beta inhibitor) combined with capecitabine (a chemotherapy drug)
- What this could lead to
- If it had worked, this could have pointed toward a new treatment option for people with chemotherapy-resistant colorectal cancer.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the combination would have been safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a vaccine boost immunotherapy against a stubborn cancer?
- What does recovery really look like after aggressive peritoneal cancer surgery?
- Chemo holidays put to the test: can scheduled breaks beat continuous treatment for advanced colorectal cancer?
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Could a liver transplant from a living donor help fight colorectal cancer that spread?